Recent clinical data show that statins may influence the phenotype of breast tumors, suggesting a new potential strategy for breast cancer prevention, that of combining statins with agents that prevent estrogen receptor (ER)-positive cancer (tamoxifen, aromatase inhibitors) [1]. Here, ESR1 is linked to cancer.